Wondering which of these peptides warrants more investigation? You should find this review helpful. Studies suggest that Sermorelin and Ipamorelin are similar because they may potentially stimulate the pituitary gland to generate more endogenous, natural growth hormone (hGH). While the effects of these two peptides are sometimes comparable, their mechanisms of action are distinct.
A comprehensive overview of Sermorelin and Ipamorelin, including their mechanisms of action, research study findings, and potential, will be provided in this essay. We will also recommend the top online provider presently providing researchers with these peptides.
A Research Peptide: What Is It?
Research peptides are peptide-bonded short sequences of amino acids. There are many types, and their lengths vary from two to fifty amino acids. Isolated peptides may come from either natural or synthetic sources. A protein is a longer chain of amino acids folded three times to form a three-dimensional structure. In contrast, peptides are usually two-dimensional and consist of shorter chains.
Sermorelin Peptide: What is it?
There is a peptide analog to growth hormone-releasing hormone (GHRH) called Sermorelin acetate, or Sermorelin for short. Although Sermorelin only comprises the first 29 amino acids of GHRH, it may possibly retain all of the pharmacological action of the full-length peptide. To rephrase, Sermorelin is the shortest peptide with this potential to be a fully functional “fragment” of GHRH.
Sermorelin Peptide: Mechanism of Action
Research suggests that Sermorelin might be effective because it is believed to imitate the action of GHRH, a naturally occurring hormone in the organism. The 44-amino acid peptide known as GHRH attaches to the growth hormone-releasing hormone receptor (GHRH-R) to increase the pituitary gland’s production and release of HGH. The action mechanism of Sermorelin is believed to be the same as that of GHRH, even though it only comprises the first 29 amino acids.
Sermorelin Peptide Potential
While reviewing the use of growth hormone secretagogues (GHS) in the contemporary approach to hypogonadal body composition, researchers suggested that Sermorelin, among other GHS, may “significantly enhance body composition while ameliorating specific hypogonadal symptoms such as [fatty tissue] and muscular atrophy.” The research usage of Sermorelin for hypogonadal research models and those of SH is “lean mass gain.”
Sermorelin Peptide and Cell Aging
Corpas et al. (1992) were the first to discover Sermorelin’s possible anti-cell aging properties; they tested the compound’s potential on growth hormone and insulin-like growth factor-1 levels in nine young male research models and ten older test subjects. “Short-term presentation of GHRH to … research models [may] reverse age-related decreases in GH and IGF-I” was the main hypothesis of the research.
After 16 weeks of receiving Sermorelin nightly, a “significant increase in skin thickness” was speculated in research models, as suggested by a single-blind, randomized, placebo-controlled experiment conducted by scientists. Among male test subjects, there was a “significant increase in lean body mass“.
According to animal studies, myocardial infarct scarring in pigs may be lessened by GHRH agonists. Nevertheless, Sermorelin has not undergone clinical studies involving animals for this specific purpose.
What follows is a description of Ipamorelin and an analysis of its potential on test models.
Ipamorelin Peptide: What is it?
Ipamorelin is a pentapeptide, which is a chain of five amino acids. The naturally occurring growth hormone-releasing peptide (GHRP-1) and its synthetic analog, Ipamorelin, have many molecular similarities. Ipamorelin differs most noticeably from GHRP-1 because it does not include the core dipeptide Ala-Trp.
Ipamorelin Peptide: Mechanism of Action
Studies suggest that Ipamorelin is a GH secretagogue that acts similarly to endogenous ghrelin by binding specifically to the GHSR-1a receptor. In response, the pituitary gland secretes growth hormone, which modulates many anabolic activities, including fat metabolism, energy expenditure, and hunger suppression. Unlike any other GHRP-receptor agonist, Ipamorelin has been hypothesized to promote GH release to a level similar to natural GHRH.
Ipamorelin Peptide and GH Secretion
As indicated by a study conducted in 1998 by K Raun et al., Ipamorelin may have the potential to encourage the production of growth hormone from primary rat pituitary cells and swine. The researchers speculated that this peptide might be viable for future clinical trials.
The European Journal of Anatomy published research in 2002 that indicated that young female rats might be stimulated to acquire weight and secrete growth hormone when presented with Ipamorelin.
Ipamorelin Peptide and Laparotomy
One study looked at using Ipamorelin in the context of postoperative ileus in 2014; however, it was short-lived. These studies were canceled because “clinical endpoints did not reach statistical relevance when comparing Ipamorelin to placebo.” On the other hand, the results of this study suggested that research models presented with Ipamorelin after open laparotomy may have faster recoveries.
Ipamorelin Peptide and Ovaries
In their study of growth hormone secretagogues (GHS) for the contemporary approach of body composition in hypogonadal male models, Deepankar et al. included Ipamorelin. “Significantly enhance body composition while ameliorating specific hypogonadal symptoms including [fatty tissue] and muscular atrophy” are believed to be the symptoms that Ipamorelin and other GHS may potentially mitigate. Weight gain is the intended research application of Ipamorelin in hypogonadal research models and models of SH.
Scientists interested in the highest quality research peptides for sale are encouraged to navigate to the Core Peptides website.
References
[i] Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999 Aug;12(2):139-57. doi: 10.2165/00063030-199912020-00007. PMID: 18031173. [ii] Xu, Z. (2016). Growth Hormone-Releasing Hormone. In Handbook of Hormones (pp. 144-e18B). Academic Press. [iii] Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992 Aug;75(2):530-5. doi: 10.1210/jcem.75.2.1379256. PMID: 1379256. [iv] Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)- NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997 May;82(5):1472-9. doi: 10.1210/jcem.82.5.3943. PMID: 9141536. [v] Bagno, L. L., Kanashiro‐Takeuchi, R. M., Suncion, V. Y., Golpanian, S., Karantalis, V., Wolf, A. & Valdes, D. (2015). Growth hormone–releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy. Journal of the American Heart Association, 4(4), e001464. [vi] Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822. [vii] Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev. 2005 Apr;85(2):495-522. doi: 10.1152/physrev.00012.2004. PMID: 15788704. [viii] Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001 Dec;86(12):5992. doi: 10.1210/jcem.86.12.8111. PMID: 11739476.
